Therapy Finder Advisor
Section Chief, Gastrointestinal Oncology Chair,
OSUCCC Gastrointestinal Disease Research Group,
Associate Professor of Medicine and Pharmacology,
The Ohio State University – James Cancer Hospital
Zaltrap (ziv-aflibercept) is a monoclonal antibody that targets the vascular endothelial growth factors VEGF-A and VEGF-B, and placenta growth factor (PGF). These growth factor proteins function in pathways important for new blood vessel growth.
Recent data from the phase III VELOUR trial that combined Zaltrap with FOLFIRI demonstrated that the combination is safe and efficacious with an acceptable toxicity profile for patients with metastatic colorectal cancer including those previously treated with Avastin (bevacizumab) (Bordonaro R, et al. 2014, Taieb J, et al. 2014). Patients benefited regardless of the timing of their first progression on a first-line oxaliplatin plus Avastin containing combination (Hoff PM, et al. 2014). A phase I study showed that Zaltrap plus FOLFIRI was safe with anti-tumor activity in patients with advanced colorectal cancer (Van Cutsem E, et al. 2014).
Serious side effects from taking Zaltrap include severe or fatal bleeding and gastrointestinal perforation. Other reported side effects include diarrhea, inflammation of or sores in the mouth, fatigue, hypertension, proteinuria (protein in urine), headache, loss of appetite, weight loss, and abdominal pain (see the FDA drug label).
Zaltrap in combination with 5-FU/leucovorin, irinotecan/FOLFIRI, is FDA approved for patients with metastatic colorectal cancer that is resistant or has progressed following an oxaliplatin containing regimen (see the FDA drug label). Additionally, ongoing clinical trials are testing the safety and efficacy of other Zaltrap containing combinations. See the trials table.
|Zaltrap, ziv-aflibercept||VEGFA, VEGFB, PGF||Sanofi-Aventis||FDA approved for: Colorectal Cancer|
Dear Therapy Finder® User:
During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.
Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.
If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.
July 6, 2015